Auvelity sales in the fourth quarter of 2024 are expected to be around $92.6 million, bringing the full-year number to around $291.4 million.

AUVELITY uses the first new oral mechanism of action in more than 60 years for MDD.1-4 AUVELITY works on the NMDA receptor, an ionotropic glutamate receptor, and on the sigma-1 receptor in the ...

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s ...

Auvelity recorded sales of $119.6 million, up 84% year over year and 24% sequentially. Sales of the drug beat our model estimate of $111.8 million. Per Axsome, around 192,000 prescriptions were ...

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY® ...

Auvelity is an oral tablet that’s prescribed for depression. It’s a brand-name drug, and it’s not available as a generic medication. The cost of Auvelity can vary, but savings are available ...

Axsome Therapeutics ' (AXSM 1.47%) psychiatric drug Auvelity could reach blockbuster status by the end of the decade -- if the company can pull through its current cash crunch. It had just over ...

Auvelity is supplied as dextromethorphan HBr 45mg/bupropion HCl 105mg extended-release tablets in 30-count bottles. The product is expected to be available in the fourth quarter of 2022. References ...

Axsome's Q3 shows strong Auvelity sales but with significant SG&A cost increases and net loss expansion. See why I downgrade AXSM stock from a buy to a hold.

Axsome Therapeutics AXSM incurred an adjusted loss of 97 cents per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $1.00. The company had incurred a loss ...